- Home
- JGH vs ANGO Comparison
JGH vs ANGO Comparison
Compare JGH & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | ANGO |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.5M | 420.2M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | JGH | ANGO |
|---|---|---|
| Price | $12.55 | $11.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 76.0K | ★ 250.2K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $11.80 | $8.36 |
| 52 Week High | $13.70 | $13.99 |
Technical Indicators
Market Signals| Indicator | JGH | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 65.32 |
| Support Level | $12.48 | $11.40 |
| Resistance Level | $12.92 | $12.72 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 40.68 | 97.73 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.